Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Support Care Cancer ; 21(2): 599-607, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22886429

ABSTRACT

BACKGROUND: While the impact of various treatments on myeloma patients' health-related quality of life (HRQL) has been reported, the impact of a treatment-free interval (TFI) is currently unclear. The aims of this study were to assess if (1) a TFI is associated with a better HRQL vs. other treatment phases and (2) the length of the TFI influences HRQL. METHODS: A cross-sectional postal survey was conducted in the UK. The survey was sent to 605 multiple myeloma patients via the charity Myeloma UK and asked patients to rate their HRQL using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), EORTC QLQ-MY20 and the EQ-5D. The results were analysed using ordinary least squares regression. RESULTS: Surveys of 402 (67 %) were returned; 370 (61 %) were considered eligible for analysis. Results demonstrated that being in a first TFI relative to other treatment phases and experiencing a longer TFI were significantly associated with better HRQL as assessed by various domains of the QLQ-C30, MY20 and EQ-5D. CONCLUSION: Patients enjoy better HRQL when in their first TFI, and the length of the TFI also positively impacts on HRQL This information may be important for patients and their physicians making treatment decisions and has implications for treatment protocols incorporating extended therapy.


Subject(s)
Antineoplastic Agents/administration & dosage , Multiple Myeloma/psychology , Quality of Life , Stem Cell Transplantation , Antineoplastic Agents/adverse effects , Critical Pathways , Cross-Sectional Studies , Drug Administration Schedule , Female , Humans , Least-Squares Analysis , Male , Middle Aged , Multiple Myeloma/therapy , Regression Analysis , Sickness Impact Profile , Survival Analysis , Transplantation, Autologous , United Kingdom
2.
QJM ; 100(4): 185-92, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17308327

ABSTRACT

We evaluated the effect of supplementation with vitamin D(3) (excluding the potential effect of calcium supplementation) on the risk of fall and fracture, primarily in postmenopausal women, using a systematic literature review of MEDLINE, EMBASE, BIOSIS and the Cochrane Database of Systematic Reviews for the period January 1985 to June 2005. Studies examining the effect of vitamin D versus placebo on the risk of fall or fracture in postmenopausal females were of particular interest. Studies of vitamin D in combination with calcium were also included where the control group was treated with calcium alone. Studies of men and women where results for men and women were not presented separately were included. Nine studies met the inclusion criteria. Our primary meta-analyses examined the effect of vitamin D(3) on the risk of fall or fracture; additional analyses examined baseline and difference between baseline and final levels of several serum and urinary biochemical markers. The pooled relative risk (RR) for vitamin D(3) preventing falls was 0.88 (95%CI 0.78-1.00). For fractures, the pooled RR for vitamin D(3) preventing non-vertebral fractures was 0.96 (95%CI 0.84-1.09) and the pooled RR for vitamin D(3) preventing vertebral fractures was 1.22 (95%CI 0.64-2.31). In a subgroup analysis of post-menopausal women, the pooled RR for vitamin D(3) preventing falls was 0.92 (95%CI 0.75-1.12) and in preventing non-vertebral fractures the pooled RR was 0.81 (95%CI 0.48-1.34). There is a trend towards a reduction in the risk of fall among patients treated with vitamin D(3) alone compared with placebo, suggesting that vitamin D(3) should be an integral part of effective osteoporosis management.


Subject(s)
Cholecalciferol/deficiency , Hip Fractures/prevention & control , Spinal Fractures/prevention & control , Vitamin D Deficiency/complications , Accidental Falls , Aged , Aged, 80 and over , Bone Density Conservation Agents/therapeutic use , Cholecalciferol/administration & dosage , Dietary Supplements , Female , Humans , Male , Middle Aged , Osteoporosis/prevention & control , Postmenopause/metabolism , Risk Factors , Treatment Outcome , Vitamin D Deficiency/diet therapy
3.
QJM ; 98(9): 667-76, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16006498

ABSTRACT

BACKGROUND: Vitamin D inadequacy has been studied extensively, due to concerns about ageing populations, associations with osteoporosis and other disorders (including non-musculoskeletal), and high prevalence. AIM: To review recent reports on the prevalence of vitamin D inadequacy among post-menopausal women with and without osteoporosis and/or other musculoskeletal diseases. DESIGN: Systematic review. METHODS: We reviewed publications in the past 10 years reporting prevalence estimates for vitamin D inadequacy, reported as serum 25(OH)D values below various levels. Thirty published studies in the English language were identified, from January 1994 through April 2004. RESULTS: In osteoporotic populations, the prevalence of 25(OH) vitamin D concentration <12 ng/ml ranged from 12.5% to 76%, while prevalence rates reached 50% to 70% of patients with a history of fracture(s) using a cut-off of 15 ng/ml. In post-menopausal women, the prevalence of 25(OH) vitamin D concentrations

Subject(s)
Postmenopause , Vitamin D Deficiency/epidemiology , Aged , Diet , Female , Fractures, Bone/etiology , Fractures, Bone/metabolism , Humans , Osteoporosis, Postmenopausal/etiology , Osteoporosis, Postmenopausal/metabolism , Prevalence , Sunlight , Vitamin D/administration & dosage , Vitamin D/blood , Vitamins/administration & dosage
4.
Clin Exp Allergy ; 35(6): 723-7, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15969661

ABSTRACT

BACKGROUND: Inadequately controlled allergic rhinitis (AR) in asthmatic patients can contribute towards increased asthma exacerbations and poorer symptom control, which may increase medical resource use. We assessed asthma-related medical resource use and attacks in asthmatic patients who did and did not have concomitant AR and were adding montelukast or salmeterol to baseline treatment with inhaled fluticasone. METHODS: A post hoc resource use analysis of a 52-week, double-blind multicentre clinical trial (Investigation of Montelukast as a Partner Agent for Complementary Therapy) [corrected] including 1490 adults with chronic asthma, aged 15-72 years, with FEV(1) 50-90% of predicted and > or =12% increase in FEV(1) after salbutamol administration, treated with either montelukast 10 mg daily or salmeterol 50 microg twice daily in addition to fluticasone 200 microg, was undertaken. Asthma-related medical resource use included medical visits (defined as either an unscheduled visit [to a general practitioner, a specialist or a non-medical provider] or a specialist visit), emergency room visits and hospitalizations during follow-up. Asthma attacks were defined as the worsening of asthma requiring unscheduled visit, emergency visit, hospitalization or oral/intravenous/intramuscular corticosteroids. RESULTS: A self-reported history of concomitant AR was identified in 60% of the patients (n=893). Univariate analysis suggests that significantly more patients with concomitant AR experienced emergency room visits (3.6% vs. 1.7%, P=0.029) and asthma attacks (21.3% vs. 17.1%, P=0.046). Multivariate analysis adjusting for treatment group, age and baseline asthma severity confirmed these results since the presence of concomitant AR in patients with asthma increases the likelihood of emergency room visit (odds ratio (OR)=2.35, 95% confidence interval (CI)=1.12-4.80) and asthma attack (OR=1.35, 95% CI=1.03-1.77). Patients with asthma alone compared with patients with both conditions did not differ in terms of unscheduled or specialist visits and hospitalizations. CONCLUSIONS: Presence of self-reported concomitant AR in patients with asthma resulted in a higher rate of asthma attacks and more emergency room visits compared with asthma patients without concomitant AR.


Subject(s)
Asthma/etiology , Emergencies , Patient Acceptance of Health Care , Rhinitis, Allergic, Perennial/complications , Acetates/therapeutic use , Administration, Inhalation , Adult , Albuterol/analogs & derivatives , Albuterol/therapeutic use , Androstadienes/administration & dosage , Anti-Allergic Agents/administration & dosage , Anti-Asthmatic Agents/therapeutic use , Asthma/prevention & control , Bronchodilator Agents/therapeutic use , Cyclopropanes , Double-Blind Method , Female , Fluticasone , Humans , Male , Quinolines/therapeutic use , Risk Factors , Salmeterol Xinafoate , Sulfides
5.
Diabetes Metab ; 29(1): 29-35, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12629445

ABSTRACT

BACKGROUND: The RENAAL study enrolled 1,513 patients with type 2 diabetes mellitus and nephropathy defined by the presence of proteinuria (urinary albumin: creatinine ratio 300 mg/g or proteinuria > 500 mg per day). Compared to placebo, losartan therapy reduced by 16% (p=0.02) the risk of a composite endpoint (doubling of baseline serum creatinine level, end stage renal disease, or death) and by 28% (p=0.002) the risk of progression to end stage renal disease (ESRD). METHODS: The objective of this study was to compare, using French economic data, the additional cost of losartan therapy with the savings in cost generated by a decrease in the number of end stage renal disease days. Prospectively collected health care resource utilization were used (N(losartan)=751, N(placebo)=762). The follow-up period was 4 years. RESULTS: The mean cumulative cost of losartan over 4 years was 1,603 euros per patient. The reduction in the number of ESRD days over 4 years in patients treated with losartan significantly decreased costs associated with ESRD by 7,438 euros per patient (CI 95%: 3,029 euros - 11,847 euros, p=0.001). Compared to the placebo group, the average cost per patient over 4 years in the losartan group was lower by 5,834 euros (CI 95%: 1,407 euros - 10,301 euros, p=0.01). CONCLUSION: In addition to the medical benefit, this analysis demonstrated the economic relevance of treatment with losartan in type 2 diabetic patients with nephropathy.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Diabetic Nephropathies/drug therapy , Kidney Failure, Chronic/prevention & control , Losartan/economics , Losartan/therapeutic use , Antihypertensive Agents/economics , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Body Mass Index , Creatinine/metabolism , Disease Progression , Double-Blind Method , Female , France , Humans , Male , Myocardial Infarction/epidemiology , Proteinuria , Racial Groups , Risk Factors , Smoking , Treatment Outcome
6.
Diabetes Metab ; 29(1): 58-64, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12629449

ABSTRACT

BACKGROUND: Our aim was to assess the quality of the medical management by GPs of hypertension and renal insufficiency in type 2 diabetic patients. METHODS: A retrospective cohort study was run on a national random representative sample of 5,518 patients presenting with type 2 diabetes mellitus treated pharmacologically by a general practitioner from April 2000 to April 2001. RESULTS: Sixty percent of patients underwent a HbA(1c) measurement during the last 6 months and among them 27% exceeded the threshold of 8%. Glomerular Filtration Rate, calculated with the Cockcroft formula, was below 60 ml/min (confirmed renal failure) in 21.9% of patients and was in the 61-80 ml/min range (probable early renal insufficiency) in 27%. Proteinuria was documented in 30.1% of patients, 13.7% of whom were positive. Microalbuminuria was documented in 36%, 15% of whom were positive. Hypertension was treated pharmacologically in 59.6% of the sample (39.3% on monotherapy, 34.2% on double combination therapy and 26.5% on triple combination therapy or more). Blood pressure was >140 and/or 80 mmHg in 81.6% of treated patients and in 27% among untreated. CONCLUSION: These findings suggest that significant progress still needs to be made in the care and treatment of type 2 diabetic patients, especially those with hypertension, in order to reduce or delay the incidence of renal and cardiovascular complications.


Subject(s)
Diabetes Mellitus, Type 2/epidemiology , Diabetic Angiopathies/epidemiology , Diabetic Nephropathies/epidemiology , Family Practice , Hypertension/epidemiology , Adult , Aged , Aged, 80 and over , Antihypertensive Agents/classification , Antihypertensive Agents/therapeutic use , Blood Pressure , Cohort Studies , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/therapy , Diabetic Angiopathies/diagnosis , Diabetic Angiopathies/physiopathology , Diabetic Nephropathies/diagnosis , Diabetic Nephropathies/prevention & control , Female , France/epidemiology , Glomerular Filtration Rate , Glycated Hemoglobin/analysis , Humans , Hypertension/drug therapy , Male , Mass Screening/methods , Middle Aged , Patient Selection , Prevalence , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...